Reported Earlier, FDA Approves Exdensur As The First Ultra-Long-Acting Biologic For Severe Asthma With Eosinophilic Phenotype

Benzinga·12/17/2025 06:28:34

语音播报

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype
Approval based on SWIFT trials showing significantly lower rate of annualized asthma exacerbations in patients receiving depemokimab versus placebo
SWIFT data included reduction in exacerbations requiring hospitalization and/or emergency department visits with depemokimab
An estimated 2 million Americans live with severe asthma and 50% continue to experience frequent exacerbations and hospitalizations requiring novel solutions